Masakazu Yamaguchi
Overview
Explore the profile of Masakazu Yamaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashimoto K, Yokokawa T, Nonomiya Y, Shibata N, Soejima A, Kobayashi K, et al.
Oncology
. 2025 Mar;
:1-23.
PMID: 40064150
Introduction: Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study...
2.
Yoshida N, Imai S, Kawakami K, Yokokawa T, Nakamura M, Aoyama T, et al.
J Cancer
. 2025 Feb;
16(5):1413-1419.
PMID: 39991570
Many studies have identified risk factors for neutropenia associated with various chemotherapies, including gemcitabine plus nab-paclitaxel (GnP). However, few studies have focused on the delayed recovery from neutropenia, which frequently...
3.
Yamaguchi M, Hada M, Iwami K
Opt Express
. 2025 Jan;
33(2):3238-3249.
PMID: 39876452
Metasurface holograms offer advantages, such as a wide viewing angle, compact size, and high resolution. However, projecting a full-color movie using a single hologram without polarization dependence has remained challenging....
4.
Yamaguchi M, Saito H, Ikezawa S, Iwami K
Nanophotonics
. 2024 Dec;
13(8):1425-1433.
PMID: 39679229
Metasurface holograms offer various advantages, including wide viewing angle, small volume, and high resolution. However, full-color animation of high-resolution images has been a challenging issue. In this study, a full-color...
5.
Iwasaki Y, Hiraide M, Taguchi H, Iehisa R, Akiyama H, Suzuki K, et al.
J Occup Environ Hyg
. 2024 Dec;
22(2):123-131.
PMID: 39656713
Hypochlorous acid (HClO), one of the major reactive oxygen species, is obtained by electrolyzing a sodium chloride solution. HClO is a safe and effective disinfectant and decomposing agent widely used...
6.
Hatori M, Fukuoka S, Kimura S, Kawakami K, Yamaguchi K, Yamaguchi M
Oncology
. 2024 Dec;
1-9.
PMID: 39647476
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanzapine. However, olanzapine is contraindicated in patients with preexisting diabetes mellitus...
7.
Suzuki K, Yokokawa T, Kawaguchi T, Takada S, Tamaki S, Kawasaki Y, et al.
Sci Rep
. 2024 Nov;
14(1):28271.
PMID: 39550497
Dexamethasone is an antiemetic drug widely used to prevent nausea and vomiting caused by anticancer drugs. However, dexamethasone can cause several side effects even after short-term administration. Therefore, the development...
8.
Asano M, Shimizu H, Yokokawa T, Suzuki W, Kawakami K, Kobayashi K, et al.
Gan To Kagaku Ryoho
. 2024 Oct;
51(9):913-918.
PMID: 39462626
Perioperative fluorouracil, epirubicin and cyclophosphamide(FEC)therapy is a standard treatment for breast cancer. However, more than 20% of patients with breast cancer who undergo FEC therapy experience febrile neutropenia(FN), for which...
9.
Tomomatsu T, Shimizu H, Yokokawa T, Fukada I, Kawakami K, Kobayashi K, et al.
Yakugaku Zasshi
. 2024 Sep;
144(9):897-904.
PMID: 39218657
This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this...
10.
Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, et al.
Cancer
. 2024 Apr;
130(17):2988-2999.
PMID: 38682652
Background: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs...